News
MedPage Today on MSN5d
Soap Recall Over Sepsis Risk; FDA Rehires Vinay Prasad; NIH Reports Patient to ICE
DermaRite Industries is recalling certain lots of its over-the-counter soaps, antiseptics, and analgesics due to ...
GlobalData on MSN6d
Prasad’s shock FDA return reignites regulatory uncertainty
Vinay Prasad resumes leadership at the FDA’s CBER two weeks after he resigned amid cell and gene therapy controversy.
BACK TO CBER — Dr. Vinay Prasad has returned to the FDA’s Center for Biologics Evaluation and Research, leaving industry and ...
HealthDay on MSN3d
Vinay Prasad Returns to FDA After Being Ousted
Dr Vinay Prasad will return to head the FDA’s Center for Biologics Evaluation and Research less than 2 weeks after being ousted.
No matter what regulatory decisions Dr. Vinay Prasad makes moving forward, the fact that he was willing to legitimize and ...
5dOpinion
Drug Approvals Hit an FDA Wall
Therapies for rare and deadly disease are dying in Marty Makary’s shop.
Vinay Prasad was reinstated as the head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA) on 11 August. He had resigned on 29 July.1 “At the FDA’s ...
Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...
WASHINGTON, DC – Dr. Vinay Prasad has been reinstated to a senior position at the Food and Drug Administration, according to ...
This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...
GlobalData on MSN10h
FDA approves Papzimeos as first therapy for HPV-caused airway disease
Precigen’s immunotherapy will likely reduce the need for repeat surgeries in recurrent respiratory papillomatosis (RRP) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback